Home
Conditions
Relapsed Neuroblastoma

Clinical trial condition

Relapsed Neuroblastoma

Explore clinical trials studying Relapsed Neuroblastoma. Study availability and eligibility vary by location and protocol.

14 public trials 9 recruiting studies

Refine in advanced search Browse all conditions

Relapsed Neuroblastoma trial results

Recruiting

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

NCT06721689

Conditions: Disease Attributes, Myosarcoma, Neoplasms, +22 more
Locations: Cedars-Sinai Medical Center Los Angeles, California, United States

University of California, San Francisco San Francisco, California, United States

Boston Children's Hospital Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Recruiting

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

NCT07211737

Conditions: Neoplasms, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, +16 more
Locations: Texas Children's Hospital Houston, Texas, United States

View Trial Details

Recruiting

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

NCT07027748

Conditions: Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +10 more
Locations: Boston Children's Hospital Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Recruiting

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

NCT07502287

Conditions: Disease Attributes, Ganglioneuroblastoma, High-risk Neuroblastoma, +15 more
Locations: Peking University Shenzhen Hospital Shenzhen, Guangdong, China

View Trial Details

Recruiting

A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

NCT07334301

Conditions: Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +8 more
Locations: Sydney Children's Hospital (SCH) Sydney, Australia

St. Anna Children´s Hospital Vienna, Austria

Cliniques Universitaires Saint-Luc (CUSL) Brussels, Belgium

Starship Children's Hospital (SSH) Auckland, New Zealand

View all 23 locations

View Trial Details

Recruiting

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

NCT05650749

Conditions: Eye Diseases, Eye Diseases, Hereditary, Eye Neoplasms, +18 more
Locations: Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States

View Trial Details

Recruiting

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

NCT06803875

Conditions: High-risk Neuroblastoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations: Boston Children's Hospital Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Recruiting

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

NCT05400603

Conditions: Neoplasms, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, +16 more
Locations: Children's Healthcare of Atlanta Atlanta, Georgia, United States

View Trial Details

Recruiting

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

NCT04211675

Conditions: Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +9 more
Locations: Nationwide Children's Hospital Columbus, Ohio, United States

View Trial Details

Completed

MIBG for Refractory Neuroblastoma and Pheochromocytoma

NCT01850888

Conditions: Metastatic Pheochromocytoma, Neoplasms, Neoplasms by Histologic Type, +12 more
Locations: University of Minnesota Masonic Cancer Center Minneapolis, Minnesota, United States

View Trial Details

Relapsed Neuroblastoma

Relapsed Neuroblastoma trial results

Related conditions